InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,845.60
(
0.88%
)
Post# of 252426
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119954
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 205459

Saturday, 11/19/2016 11:25:19 AM

Saturday, November 19, 2016 11:25:19 AM

Post# of 252426
EXAS—CEO/COO/CSO sold cumulative $28M of stock during the past week or so:

https://www.sec.gov/Archives/edgar/data/1124140/000120919116150334/xslF345X03/doc4.xml
https://www.sec.gov/Archives/edgar/data/1124140/000120919116150333/xslF345X03/doc4.xml
https://www.sec.gov/Archives/edgar/data/1124140/000120919116150335/xslF345X03/doc4.xml

Cologuard is a fine product, but selling a diagnostic for colorectal cancer is a tough way to make money.

EXAS lost $38M in 3Q16 and $130M during 2016’s first nine months. Cologuard was approved by the FDA more than two years ago (#msg-105198793).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up